EZH2 and prostate cancer: For example, the expression level of histone lysine methyltransferase EZH2 which mainly catalyze H3K27me3 is higher in the breast cancer, prostate cancer and bladder cancer, and has been used as a prognostic marker in breast cancer and metastatic prostate cancer [34, 35].